Review

The role of miR-320 in glucose and lipid metabolism disorder-associated diseases

Hengzhi Du, Yanru Zhao, Zhongwei Yin, Dao Wen Wang, and Chen Chen

Division of Cardiology, Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Corresponding author: Chen Chen. Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, 1095# Jiefang Ave., Wuhan 430030, China. Tel/fax: 86-27-6937-8422. Email: chenchen@tjh.tjmu.edu.cn

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Received: 2020.09.21; Accepted: 2020.11.21; Published: 2021.01.01

Abstract

Glucose and lipids are important nutrients that provide the majority of energy for each organ to maintain homeostasis of the body. With the continuous improvement in living standards, the incidence of metabolic disorder-associated diseases, such as diabetes, hyperlipidemia, and atherosclerosis, is increasing worldwide. Among them, diabetes, which could be induced by both glucose and lipid metabolic disorders, is one of the five diseases with the highest incidence and mortality worldwide. However, the detailed molecular mechanisms underlying glucose and lipid metabolism disorders and target-organ damage are still not fully defined. MicroRNAs (miRNAs) are small, non-coding, single-stranded RNAs, which usually affect their target mRNAs in the cytoplasm by post-transcriptional regulation. Previously, we have found that miR-320 contributed to glucose and lipid metabolism via different signaling pathways. Most importantly, we identified that nuclear miR-320 mediated diabetes-induced cardiac dysfunction by activating the transcription of fatty acid metabolic genes to cause lipotoxicity in the heart. Here, we reviewed the roles of miR-320 in glucose and lipid metabolism and target-organ damage.

Key words: miRNA; glucose and lipid metabolism; diseases

Introduction

Glucose metabolism and lipid metabolism usually interact with each other. Glucose and lipid metabolism stability is important for maintaining the function of all organs of the body. However, with the rapid increase in the prevalence of high-fat or high-glucose diets, glucose and lipid metabolism-associated diseases have attracted increasing attention [1]. For example, glucose and lipid metabolism disorder is involved in various diseases such as obesity [2], diabetes mellitus [3], hypertension [4], dyslipidemia [5], nonalcoholic fatty liver disease [6], and atherosclerosis [7]. Glucose and lipid metabolism-associated diseases also participate in the occurrence of their complications. For example, extreme hyperglycemia may lead to ketoacidosis, which damages the vasculature and nervous system [8]. Moreover, the glucose and lipid metabolism disorder in diabetes can destroy various organs, especially the eyes, kidneys, nerves, heart and blood vessels [9]. However, the underlying molecular mechanisms of glucose and lipid metabolism and its involvement in multiple target-organ damage are not fully explored.

MicroRNAs (miRNAs) are small conserved non-coding RNAs of 19-25 nucleotides that have crucial effects on gene regulation in various biological processes and diseases mainly by inhibiting target mRNA translation or promoting target mRNA degradation [10]. Initial miRNA-associated studies were mainly focused on cancer development, cardiovascular diseases, and metabolic diseases. It was found that the expression profile of miRNAs was changed in plasma and tissue samples under disease conditions such as cancer [11], hyperlipidemia [12], hyperglycemia [13], endothelial cell dysfunction [14] and diabetes [15]. We also identified the altered expression of circulating miRNAs in patients with coronary heart disease (CHD), compared with healthy
individuals, among which the expression level of miR-320 was positively correlated with the risk of CHD [16]. The functions of these changed miRNAs including miR-320 were gradually discovered in various diseases. For example, nuclear miR-320 mediated diabetes-induced cardiac dysfunction by activating transcription of fatty acid metabolic genes to cause lipotoxicity in the heart [17].

In humans, the miR-320 family consists of miR-320a (chr8), miR-320b (chr1), miR-320c (chr18), miR-320d (chr13 and chrX), and 320e (chr19), among which miR-320a is present in all primates [18]. miR-320 is encoded directly upstream of the cell cycle gene POLR3D, which is a conserved subunit specific to RNA polymerase III [19, 20].

Among these metabolism associated-miRNAs, our previous study showed that miR-320 was markedly elevated in the peripheral blood of patients with CHD [16]. Meanwhile, we discovered various roles of miR-320 in metabolism-associated injuries including aggravating diabetic cardiac dysfunction [17], promoting atherosclerosis [16] and deteriorating diabetic nephropathy [21]. In this review, we focused on the current knowledge about the roles of miR-320 in glucose and lipid metabolism and the target-organ damage.

**miR-320 serves as a potential biomarker for glucose and lipid metabolism-associated diseases**

It has been clarified that miRNAs are highly stable in bodily fluids, which makes them feasible candidates for non-invasive biomarkers [22]. The expression profiles of miRNAs in clinical specimens could be identified by high-throughput RNA sequencing or real-time PCR assays with high sensitivity and specificity [23]. Accumulating evidence suggests that miRNAs can be used as potential biomarkers for disease diagnosis and prognosis [24, 25]. Regarding the metabolism of glucose and lipid, multiple studies have found that the expression level of miR-320 was changed in the blood or tissues from patients or animal disease models with metabolic syndrome [26], diabetes and its complications [27].

**miR-320 is a potential biomarker for diabetes**

Diabetes is a systemic metabolic disease characterized by insulin resistance and relative underproduction of insulin [28], which in turn will impair the function of other organs including the heart, liver and kidney through systemic metabolic disorders [29], such as hyperglycemia and dyslipidemia [30, 31]. The development of biomarkers for early diagnosis could be helpful in identifying individuals at risk of developing diabetes or related complications [27]. The traditional diagnosis of type 2 diabetes (T2DM) is generally based on the biochemical examinations of fasting plasma glucose (FPG) [32], oral glucose tolerance test (OGTT) and glycated hemoglobin (HbA1C) levels [33]. Moreover, C-reactive protein, adipokines, and incretins were regarded as candidate novel biomarkers for T2DM [34, 35]. However, the risk assessment of related complications could not be defined by these biomarkers, which requires the discovery of novel biomarkers [36].

To explore the potential molecules that could predict the development and progression of diabetes mellitus, multiple studies have analyzed the miRNA profiles in serum, plasma or blood cells to find candidate miRNAs [37, 38]. In 2010, Zampetaki et al. identified the T2DM-related expression pattern of circulating miRNAs by analyzing blood samples from over 800 individuals randomly selected from the Bruneck population (Bolzano Province, Italy) for the first time [37]. This prospective study revealed lower plasma levels of miR-320 in 80 individuals with either pre-diabetes or T2DM. It was noteworthy that the change in miR-320 was earlier than the diagnosis of T2DM, which suggested a possibility that circulating miR-320 might be a predictor for the ongoing T2DM and its complications. On the other hand, Karolina et al. detected an upregulation of circulating miR-320 in patients with T2DM and observed a positive correlation between the miR-320 level and fasting blood glucose level by measuring miRNA expression in the blood and exosomes from 265 patients with different health conditions associated with metabolic syndrome [26]. In addition to the expression profile of miRNAs in diabetes, Ling et al. have shown that miR-320 was also upregulated in insulin-resistant 3T3-L1 adipocytes compared with normal adipocytes [39]. It is worth mentioning that Zampetaki et al. detected a downregulation of circulating miR-320 in patients with T2DM, which is contradictory to the findings of others. The reasons for these different observations might be the following: 1) the detection method and 2) the limited sample size or the different cohorts enrolled in various studies. Specifically, instead of testing each sample individually, Zampetaki et al. pooled the samples to detect miRNA levels in plasma; this sampling strategy might lead to the overall decrease because of certain particular extremum. The limited sample size or the different cohorts may also have contributed to the differences observed. For example, Zampetaki et al. identified multiple candidate miRNAs, including decreased plasma miR-20b and miR-150, in 80 prevalent DM individuals. However, others also reported increased...
circular miR-320a. As a result, it is necessary to further expand the sample size and strictly design prospective studies to identify whether miR-320 could serve as a biomarker for diabetes.

miR-320 is a potential biomarker for atherosclerosis

Atherosclerosis is a chronic disease characterized by the accumulation of plaques, which are characterized by large necrotic cores with thin fibrous caps, cholesterol deposits, inflammatory cells and calcifications within the arteries [41], and is a leading cause of death and loss of productive life years worldwide [42]. Currently, imaging biomarkers are the major method to diagnose atherosclerosis clinically [43]. The traditional way to diagnose atherosclerosis is by using ultrasound, which may be subjective. In recent years, computed tomography angiography (CTA) has also been commonly used, but there are still defects such as contrast agent allergy, false positives, and limited assessment of the plaque rupture or vascular blockage risk. Some studies observed that the miRNA expression profiles were changed in patients with coronary atherosclerosis, which might be potential biomarkers for the diagnosis and prognosis of atherosclerosis [44, 45]. For example, Wang et al. detected 9 candidate miRNAs in the plasma exosome from 42 patients with coronary atherosclerosis and identified miR-30e as a novel diagnostic biomarker for coronary atherosclerosis [46].

Coronary heart disease (CHD), mainly derived from the progression of atherosclerosis, is also one of the leading causes of death worldwide [47, 48]. It was reported that individuals with diabetes mellitus suffer from a higher incidence of CHD compared with those without diabetes [49]. Furthermore, the major cause of death in patients with CHD is the rupture of atherosclerotic plaques leading to the formation of a thrombus and causing a myocardial infarct. However, the current diagnosis of CHD is established by coronary angiography or CTA, which have shown limited information for the early diagnosis and prognosis assessment of CHD [50, 51].

With the study on CHD, researchers found that miRNAs could be potential biomarkers for the early diagnosis and prognosis assessment of CHD. For example, Zhou et al. performed miRNA microarray analysis in the plasma of 3 patients with CHD patients and 3 healthy controls and observed that miR-206 and miR-574-5p were significantly upregulated in patients with CHD by performing quantitative real-time PCR (qRT-PCR) analysis of miRNA expression in plasma of another 67 patients with CAD and 67 healthy controls, which suggested the sensitive and specific diagnostic value of miRNAs for CHD [52]. Zhong et al. identified that miR-142-3p and miR-17-5p might be potential targets for follow-up research in evaluating biomarkers of CHD by analyzing the miRNA expression profiles of circulating miRNAs from 12 patients with CHD and 6 healthy controls [53]. However, it is worth mentioning that the sample number adopted in the above studies is limited and it would be better to increase the number of specimens, thereby increasing the confidence, which would make the results of the studies more convincing. Meanwhile, the expression of miR-320 was also changed in the patients with CHD. In a previous study from our group, we performed miRNA microarray analysis in the peripheral blood of 10 patients with CHD, 10 CHD high-risk individuals and 10 healthy controls and found that miR-320 was highly expressed in patients with CHD [16]. Moreover, miR-320 was a key regulator contributing to multiple aspects of atherogenesis, which suggested that miR-320 might be a potential biomarker for atherogenesis and CHD [16]. Mechanically, we found that SPI could transcriptionally up-regulate lsa-miR-320a expression in endothelium cell [16]. Recently, Su et al. profiled miRNAs in the plasma from 203 patients with CHD and 144 age-matched controls (126 high-risk controls and 18 healthy volunteers) and showed that miR-320e was increased in CHD patients [54]. Moreover, correlation analysis indicated that miR−320e could be a better biomarker for CHD diagnosis compared to most conventional clinical factors, such as apolipoprotein A (ApoA), apolipoprotein B (ApoB), and LPA [54]. Meanwhile, Liu et al. also performed miRNA microarray analysis in an OPG−/− mouse model to identify miRNAs involved in vascular calcification, a major characteristic of atherosclerosis [55]. They found that miR-320 was decreased compared with control mice and suggested that miR-320 might play an important role in the progression of vascular calcification [55].

It is worth mentioning that hyperlipidemia, a group of disorders characterized by excessive lipids, is an independent risk factor for diabetes and CHD [56]. Many studies have shown that patients with diabetes or CHD have lipid metabolic disorders including elevated plasma total cholesterol, triacylglycerol (TRG), and LDL and decreased HDL [57, 58]. Interestingly, researchers have found that miR-320 might be a highly specific miRNA for risk assessment of hyperlipidemia. For example, Xu et al. collected the serum samples and clinical data of 122 patients with hyperlipidemia and 168 healthy subjects...
to detect the circulating miRNA profile by miRNA microarray analysis [12]. They detected 22 changed miRNAs, including upregulation of miR-320b, miR-320e, miRNA-191-3p, miRNA-933, and miRNA-425-3p, in the peripheral circulation of patients with lipid metabolism disorder, and these miRNAs could be risk assessment factors for hyperlipidemia.

**miR-320 is a potential biomarker for adiposity**

With the rapid increase in the prevalence of high-fat or high-glucose diets, adiposity, which often induces insulin resistance, type 2 diabetes, and cardiovascular diseases, has become a major public health problem worldwide [59]. To investigate whether miRNAs are involved in adiposity, researchers performed miRNA expression analysis in human samples [60-62]. For example, Pescador et al. collected the serum samples and clinical data of 30 patients with type 2 diabetes, 20 obese patients, 16 obese patients with type 2 diabetes and 20 healthy controls to detect the changed circulating miRNAs by miRNA microarray analysis [63]. They discovered that 3 microRNAs, namely, miR-138, miR-15b, and miR-376a, were potential predictive biomarkers in obesity. Meanwhile, Eiji et al. also observed that miR-320 might be a biomarker for obesity [64]. They analyzed the circulating miRNAs profile in 526 individuals who participated in health examinations and found that the altered expression levels of miR-320 were significantly associated with visceral adipose tissue levels, which suggested that miR-320 might be a potential biomarker for adiposity.

**miR-320 is a potential biomarker for nonalcoholic fatty liver disease**

The liver is the most important organ in the body to maintain lipid homeostasis, and hyperlipidemia can further aggravate the accumulation of lipids in hepatocytes leading to nonalcoholic fatty liver disease [65]. Kagawa et al. collected plasma samples from steatosis model mice and found upregulated miR-320 by RNA-sequencing, which suggested that miR-320 might be a potential biomarker for nonalcoholic fatty liver disease [66]. In conclusion, the abnormal expression of miR-320 was detected in many metabolic diseases, including diabetes and its complications, through miRNA microarray analysis, which indicated that miR-320 might be a potential biomarker for these diseases (Figure 1).

---

**Figure 1.** miR-320 serves as a potential biomarker for glucose and lipid metabolism disorder-associated diseases, including adiposity and atherosclerosis, coronary heart disease and nonalcoholic fatty liver disease.
The effects of miR-320 on glucose and lipid metabolism-associated diseases

By analyzing the miRNA expression profile in diseases related to glucose and lipid metabolic disorders, researchers have found that miR-320 might be a potential biomarker. Further, the biological functions of miR-320 under these conditions were investigated.

The effects of miR-320 on glucose and lipid metabolism in different target cells

Different cell types may contribute to certain pathological processes via multiple mechanisms. Here, we summarized the effects of miR-320 on glucose and lipid metabolism in white adipocytes, cardiomyocytes, endothelial cells and cancer cells.

The effects of miR-320 on glucose and lipid metabolism in white adipocytes

Adipocytes in the body have a variety of important physiological functions including storing triglycerides, maintaining blood glucose homeostasis, and providing energy as the body needs it. These processes are regulated by insulin directly [67]. Under normal conditions, insulin binds to the insulin receptor on the plasma membrane of adipocytes [68] and initiates downstream metabolic signaling by recruiting phosphotyrosine-binding scaffold proteins, which in turn activate phosphoinositide-3-kinase (PI3K) [69-72]. The critical physiological functions of this signaling pathway in white adipose tissue include the suppression of lipolysis and stimulation of glucose uptake and lipogenesis [67]. It was reported that miR-320 could suppress this signaling pathway by targeting the p85 subunit of PI3K [39]. Using miRNA microarray analysis, Ling et al. compared miRNA expression profiles between normal insulin-sensitive 3T3-L1 adipocytes and 3T3-L1 adipocytes rendered insulin resistant following treatment with high glucose and high insulin and found that the expression of miR-320 increased significantly compared with the control group. In addition, they found that the p85 subunit of PI3K was a potential target of miR-320 in adipocytes, which suggested that miR-320 could suppress the insulin-PI3K pathway to affect glucose and lipid metabolism.

In addition to the abovementioned approaches, miR-320 can also affect the glucose and lipid metabolism of adipocytes through the endoplasmic reticulum (ER) stress pathway [73]. The ER is a critical organelle for protein synthesis, folding and modification, lipid synthesis and calcium storage [74]. Due to aging, genetic mutation or environmental stress, unfolded proteins accumulate in the ER [75], which will induce ER stress, the disruption of ion balance in the ER or serve as an obstacle to protein processing and transportation [76]. It has been reported that ER stress could lead to decreased insulin action by disrupting insulin receptor signaling [77] and induce lipolysis in adipocytes to maintain energy homeostasis [78]. Interestingly, Lu et al. indicated that the expression level of miR-320 in omental adipose tissues and blood samples of 24 obese patients was upregulated compared with healthy donors. Further, they showed that inhibition of the upregulated miR-320 could ameliorate ER stress and the inflammatory response in 3T3-L1 adipocytes.

Together, the increased expression of miR-320 in stressed adipocytes suppressed glucose uptake and lipogenesis while inducing lipolysis via the insulin-PI3K pathway and ER stress signaling (Figure 2).

The effects of miR-320 on glucose and lipid metabolism in cardiomyocytes

Under normal circumstances, the heart needs a continuous energy supply to support both electrical and mechanical activities, which are mainly produced by mitochondrial oxidative phosphorylation [79]. The substrate of oxidative phosphorylation is acetyl-CoA, which comes from the oxidation of fatty acids and pyruvate [80, 81]. Therefore, mitochondrial dysfunction could affect glucose and lipid metabolism, reducing the normal physiological activities of cardiomyocytes. It has also been reported that miR-320 could induce mitochondrial apoptosis [82]. In a mouse model of ischemia–reperfusion injury (I/R), Tian et al. found that the level of miR-320 is substantially higher than that in the corresponding controls and the loss of mitochondrial membrane potential was enhanced. Additionally, they found that AKIP1 was the target of miR-320. AKIP1 plays an essential role in maintaining the function of mitochondria including promoting mitochondrial respiration and improving mitochondrial coupling efficiency while simultaneously attenuating mitochondrial ROS emissions [83-86]. The overexpression of miR-320 could inhibit the expression of AKIP1, which might induce the mitochondrial apoptotic pathway and influence glucose and lipid metabolism in cardiomyocytes in the case of ischemia–reperfusion (I/R) injury.

Interestingly, in addition to the pathway described above, miR-320 plays an essential role in cardiomyocyte apoptosis via other signals. Song et al. found that the expression level of miR-320 was significantly upregulated in a rat model of myocardial I/R injury [87]. In I/R injury, miR-320 induced...
cardiomyocyte apoptosis by reducing the expression of IGF-1 [88]. It is remarkable that insulin significantly reduced the mortality of patients with myocardial ischemia [89, 90]. Using an ischemia cell model, Ni et al. found that miR-320 was significantly upregulated after ischemia but decreased to basal levels after insulin pretreatment, suggesting that inhibition of miR-320 was involved in the cardioprotective effects of insulin against myocardial ischemia [91]. They also found that the target of miR-320 was Survivin, a key regulator in cell apoptosis [92, 93]. Regarding myocardial ischemia, these findings taken together suggest that miR-320 could enhance the apoptosis of cardiomyocytes via multiple pathways.

Although insulin could protect cardiomyocytes as described above, this effect is weakened or absent in diabetes. Moreover, in the early stages of diabetes, fatty acid intake in cardiomyocytes by CD36 is increased due to the lack of insulin or insulin resistance [29, 94]. Recently, we found the miR-320 could promote the process of fatty acid intake in cardiomyocytes [17]. The upregulation of miR-320 was observed in cardiomyocytes from db/db mice compared to controls. Interestingly, we noted that miR-320 was not only present in the cytoplasm but also in the nucleus of mouse myocytes. Moreover, we revealed that miR-320 could directly target to the CD36 promoter by forming a complex with Ago2 to enhance CD36 transcription, resulting in increased fatty acid transport. To further validate the function of nuclear miR-320 in cardiomyocytes, the Ago2-knockdown cardiomyocyte cell line was established using CRISPR-Cas9 technology. We found that CRISPR-Cas9-mediated Ago2 knockdown abolished miR-320-induced transcriptional remodeling, and nuclear Ago2 re-expression restored the effects of miR-320 in the nucleus [95]. In addition, further analysis in our study suggested that Ago2/miR-320

![Figure 2](int.ijbs.com/issue) The effects of miR-320 on glucose and lipid metabolism in white adipocytes. The most critical physiological functions of insulin action in white adipose tissue are suppression of lipolysis and stimulation of glucose uptake through translocation of GLUT4 to the plasma membrane. (a) miR-320 could target the p85 subunit of PI3K to induce insulin resistance and suppress glucose uptake and lipogenesis and affect the process of lipolysis. (b) miR-320 induces ER stress to reduce the action of insulin and promote lipolysis. PI3-K, phosphoinositide-3-kinase; GLUT4, glucose transporter 4; IRS1, insulin receptor 1.
complexes could target Cep57 or Fscn2 promoter DNA for transcriptional regulation and affect the process of glucose and lipid metabolism. It is worth noting that there has been no report on the effect of Cep57 or Fscn2 on glucose and lipid metabolism. Despite the increased FFA use in diabetic hearts, excessive fatty acid leads to intracellular lipid accumulation, which activates PPAR-α signaling, leading to the increased transcription of genes involved in FFA oxidation and the excess generation of reactive oxygen species (ROS) in mitochondria [96-98]. Moreover, it has been proven that PPAR-α signaling could increase the expression of CD36 to improve the transport of FFA [99], which might synergize the effects of miR-320 in cardiomyocytes.

In conclusion, miR-320 could damage cardiomyocytes not only by promoting apoptosis but also via glucose and lipid metabolism disorder (Figure 3).

The effects of miR-320 on glucose and lipid metabolism in endothelial cells

Damage to myocardial microvascular endothelial cells (MMVECs) is one of the key processes in diabetic cardiomyopathy [100, 101], which leads to insufficient myocardial angiogenesis, represented by reduced coronary artery collateral vessel formation and low capillary density [102, 103]. In addition to affecting glucose and lipid metabolism in cardiomyocytes, miR-320 was also functional in endothelial cells in diabetic cardiomyopathy [16].

As mentioned above, we found that miR-320 is a potential biomarker for atherosclerosis and CHD. Moreover, we discovered that miR-320 inhibited proliferation and induced apoptosis of endothelial cells by targeting Serum Response Factor (SRF) [16]. Meanwhile, Wang et al. found that miR-320 was upregulated in MMVECs in type 2 diabetic Goto-Kakizaki (GK) rats by using miRNA microarray [104]. The upregulation of miR-320 decreased the expression of Insulin-like Growth Factor 1 (IGF-1), which could promote angiogenesis, and finally decreased the angiogenic response to diabetic microvascular injury [105].

Figure 3. The effects of miR-320 on glucose and lipid metabolism in cardiomyocytes. (a) In an ischemia–reperfusion injury (I/R) model, miR-320 could target AKIP1 to induce the mitochondrial apoptotic pathway and suppress the oxidative metabolism of glucose and lipid in cardiomyocytes. (b) miR-320 reduces the expression of IGF-1 to induce cardiomyocyte apoptosis in the case of I/R injury. (c) miR-320 reduces the expression of Survivin to induce cardiomyocyte apoptosis. (d) miR-320 targets to the CD36 promoter directly by forming a complex with Ago2 to enhance CD36 transcription and promote fatty acid transport. (e) The lipid accumulation activates PPAR-α signaling leading to the increased transcription of many genes involved in FFA oxidation and increases the expression of CD36 to improve the transport of FFA. AKIP1, A kinase interacting protein 1; IGF-1, insulin-like growth factor 1.
Figure 4. The effects of miR-320 on glucose and lipid metabolism in endothelial cells. (a) In endothelial cells, miR-320 decreased the expression of the SRF gene, leading to the inhibition of angiogenesis. (b) miR-320, derived from cardiomyocytes via exosomes, decreased the expression of the IGF-1 gene, leading to the downregulation of VEGF expression to inhibit angiogenesis. (c) miR-320 decreased the expression of VEGFA to inhibit angiogenesis in the case of hyperglycemia. (d) In the hyperlipidemic state, lncRNA XIST and miR-320 inhibit the protein level of NOD2 leading to apoptosis of endothelial cells. SRF, serum response factor; VEGF, vascular endothelial growth factor; VEGFA, vascular endothelial growth factor A; NOD2, nucleotide binding oligomerization domains; MMVECs, myocardial microvascular endothelial cells; HUVECs, human umbilical vein endothelial cells.

Interestingly, it was reported that the anti-angiogenic effect of miR-320 on endothelial cells could also be mediated by exosomes from cardiomyocytes [106]. Wang et al. observed that cardiomyocytes isolated from type 2 diabetic rats elicited inhibitory effects on angiogenesis through the exosomal transfer of miR-320 into endothelial cells.

In addition to MMVECs, Feng et al. showed that miR-320 could regulate glucose-induced gene expression in human umbilical vein endothelial cells (HUVECs), including Endothelin-1 (ET-1), Vascular Endothelial Growth Factor (VEGF) and Fibronectin (FN), which also participate in angiogenesis [107]. Furthermore, Gao et al. found that the miR-320/VEGFA axis was crucial to high-glucose-induced metabolic memory during HUVEC dysfunction and might be involved in the pathology of diabetes [108]. In the hyperlipidemic state, oxidative low-density lipoprotein (ox-LDL) induces endothelial dysfunction and apoptosis by increasing oxidative stress in endothelial cells [109]. Recently, Xu et al. suggested the IncRNA XIST silencing alleviated EC injury via regulation of the miR-320/NOD2 axis [110].

In conclusion, miR-320 also impairs endothelial cell function in diabetic cardiomyopathy, which might provide a new therapeutic strategy for the treatment (Figure 4).

The effects of miR-320 on glucose and lipid metabolism in cancer cells

Either under normal physiological or pathological conditions, glucose can be converted into pyruvate by the glycolytic pathway to maintain the normal physiological metabolism of cells [111]. Metabolic abnormalities exist in a lot of different cancers including solid tumors of the liver, lung, pancreas, skin, stomach, and uterus as well as acute lymphocytic and myeloid leukemias [112]. Abnormal tumor metabolism may be caused by the genetic alterations acquired by tumors modifying their biochemical pathways and tumor dynamic microenvironment [113]. It has been reported that tumor cells showed higher rates of glycolysis known as the "Warburg effect", lactate production, changes in lipid synthesis and oxidation occur due to mitochondrial respiration injury and hypoxia, which were frequently associated with the resistance to therapeutic agents [114], compared with corresponding normal tissues [115]. For example, Nieman et al. showed that ovarian cancer cells...
induced fat cell-driven lipolysis and increased the availability of lipids for uptake to rapid division [116]. Gastric cancer exhibited a Warburg effect which involving an enhanced uptake of glucose and glycolysis to provide energy under aerobic conditions [117]. It is worth mentioning that increased risk of metabolic syndrome was observed in acute lymphoblastic leukemia (ALL) survivors compared with general population [118, 119]. Moreover, Poulain et al. showed that AML cells promoted glycolysis and led to glucose addiction to rapid division by constantly over activating mTORC1 signaling [120].

Studies have reported that miR-320 was downregulated in various types of cancers [121-123]. As a negative regulator, the overexpression of miR-320 inhibited the proliferation and differentiation of a variety of cancer cells, which in turn suppressed the development and progression of cancer [124, 125]. Importantly, miR-320 might also influence the development of cancer by regulating glucose and lipid metabolism. Tang et al. showed that miR-320 played an essential role in the glycolytic pathway during mitochondrial oxidative stress in lung cancer [126]. They found that Ets1 (ETS proto-oncogene 1), a transcription factor, could bind to the promoter of hsa-miR-320a in response to H2O2 treatment, thereby negatively regulate the transcription of miR-320 in several cell types [126]. As the expression of miR-320 decreased, the level of glycolytic enzyme muscle-type phosphofructokinase (PFKm) protein, a crucial rate-limiting enzyme of glycolysis, was elevated, thus enhancing the glycolysis process in lung cancer [127].

In addition to glucose metabolism, some studies showed that miR-320 could inhibit the proliferation and differentiation of cancer cells by affecting lipid metabolism. For example, Lei et al. found that miRNA-320 inhibited non-small cell lung cancer cell proliferation, migration, and invasion by targeting fatty acid synthase [128]. Tang et al. suggested that miRNA-320 also inhibited osteosarcoma cell proliferation by directly targeting fatty acid synthase [129]. Fatty acid synthase, which is highly expressed in most human carcinomas, is a key lipogenic enzyme that catalyzes the terminal steps in the de novo biogenesis of fatty acids in cancer pathogenesis [130] and plays critical roles in cancer proliferation and metastasis [131]. miR-320 inhibited the fatty acid synthase directly, which in turn reduced the de novo biogenesis of fatty acids in cancer cells and finally suppressed cancer cell proliferation, migration, and invasion.

Exosomes are naturally released from living cells and have been well recognized to play critical roles in mediating cell-to-cell communication [132]. It is worth mentioning that the current studies about the exosomal transfer of miR-320 mainly focus on cancers [133-135]. For example, Stevic et al. determined the miRNA profiles in exosomes from plasma of 106 epithelial ovarian cancer patients, 8 ovarian cystadenoma patients, and 29 healthy women, and they found that miR-320 was significantly enriched in the exosomes from plasma of epithelial ovarian cancer patients as compared to those of healthy women [133]. Wan et al. detected that exosomal transfer of miR-320 from leukemia cells to bone marrow mesenchymal stromal cells was an important mediator of leukemia progression and might be a potential therapeutic target for CML [135]. Moreover, Manterola et al. demonstrated that miR-320 in the exosomes isolated from the serum of glioblastoma multiforme patients could serve as a potential diagnostic biomarker for glioblastoma multiforme [136]. However, the clinical and laboratory data about the exosomal transfer of miR-320 in glucose and lipid metabolism-associated diseases are still limited.

In summary, miR-320 played important roles in regulating glucose and lipid metabolism in various cancer cells, specifically by depriving the energy supply (Figure 5).

The effects of miR-320 on glucose and lipid metabolism in different target organs

Diabetes is associated with microvascular and macrovascular complications as a result of disordered glucose and lipid metabolism [29]. These complications can lead to impaired function of other organs including the heart, liver and kidney through systemic metabolic disorders as described above [29]. We are reviewing the effects of miR-320 on glucose and lipid metabolism in the kidney, liver, and pancreas during diabetes.

The effects of miR-320 on glucose and lipid metabolism in the kidney during diabetes

To study the effects of miR-320 on glucose and lipid metabolism in the kidney, Chen et al. used a miRNA microarray assay to measure the expression profile of miRNAs in a mouse model of early diabetic nephropathy (DN) [137]. They found that miR-320 was increased significantly in the DN mice. Moreover, our lab also showed that miR-320 increased ROS production and induced podocyte apoptosis to promote the development of DN [21]. In the kidneys of diabetic mice, we detected that the level of miR-320 was increased. Overexpression of miR-320a could aggravate renal disfunction in DN by targeting MafB and downregulating Nephrin, a key component of the glomerular slit diaphragm that is critical in preventing proteinuria, and Gpx3, an antioxidative stress enzyme in podocytes that increases ROS.
The effects of miR-320 on glucose and lipid metabolism in the liver during diabetes

In addition to medication such as insulin and antidiabetic drugs, surgery is an important treatment strategy for diabetes. For example, duodenal-jejunal bypass (DJB) has been shown to be an effective surgical treatment for T2DM [141]. Meanwhile, miR-320 might mediate the therapeutic effects of DJB in T2DM. Wei et al. found that 5 miRNAs including miR-320 were downregulated significantly in the liver after DJB [142]. Further, they found that miR-320 could target AdipoR1, which regulated glucose and fatty acid metabolism partly via the activation of adenosine monophosphate-activated protein kinase (AMPK) [143-145]. This suggested that DJB could reduce the expression of miR-320 and increase AdipoR1, which regulated hepatic insulin sensitivity to improve T2DM. Significantly, their study directly showed that the abnormal expression of miR-320 could lead to the disorder of glucose and lipid metabolism in the liver, thus promoting the development of diabetes.

Figure 5. The effects of miR-320 on glucose and lipid metabolism in kidney, liver, and pancreas during diabetes. (a) Overexpression of miR-320 mediated by diabetes could inhibit the expression of MafB to reduce the level of Nephrin and Gpx3 and promote the development of DN. (b) Duodenal-jejunal bypass surgery inhibits the expression of miR-320 in the liver and increases AdipoR1 levels to promote insulin sensitivity via activation of AMPK, leading to increased glucose uptake and fatty acid oxidation, which alleviates the development of diabetes. (c) JTXK could increase the level of miR-320, thereby mediating the effect of PI3K-Akt and FoxO signaling to inhibit the apoptosis of β-cells and exert anti-diabetic effects in the pancreas. Gpx3, glutathione peroxidase 3; AMPK, adenosine monophosphate-activated protein kinase; AdipoR1, adiponectin receptor 1; FoxO, forhead box class O; JTXK granule, Jiang Tang Xiao Ke granule.
The effects of miR-320 on glucose and lipid metabolism in the pancreas during diabetes

A decrease in the number of functional insulin-producing beta cells is the key factor in the development of T2DM and hyperglycemia, while dyslipidemia, cytokines, leptin, autoimmunity, and some sulfonylureas may contribute to the damage of beta cells [146]. Interestingly, Mo et al. found that miR-320 was one of the targets of Jiang Tang Xiao Ke (JTXK) granules in mouse pancreatic tissue [147]. JTXK is a Chinese herbal formula that has been used clinically to treat T2DM for decades [148]. Using miRNA microarray assays, the expression of miR-320 was found to be changed in pancreatic tissue, and miR-320 was predicted to mediate the anti-diabetic effect of JTXK via PI3K-Akt and the FoxO signaling pathway. Though this provided a preliminary strategy to improve the function of beta cells using Chinese herbal medicine, the detailed mechanism remains to be further studied.

In conclusion, miR-320 could participate in multiple organ damage in glucose and lipid metabolism disorder-associated diseases, which provides a potential “multiple-effects” therapeutic target of these diseases (Figure 6).

Conclusion

Although glucose and lipid metabolism disorder-associated diseases have been recognized for many years, the effective prevention and treatment strategies remain elusive. In this article, we first reviewed that miR-320 might be a potential biomarker for metabolic diseases, such as obesity, diabetes, and its complications, which provided a new diagnostic strategy for these diseases. Then, we systematically described the effects of miR-320 on glucose and lipid metabolism disorder-associated diseases. For clinical application, multiple studies suggested that the aberrant expression of miRNAs played essential roles in various diseases, which provided a new therapeutic strategy [149]. Here, we reviewed the diagnostic and therapeutic strategies for glucose and lipid metabolism disorder-associated diseases by targeting miR-320. Moreover, we provided a summary table to better illustrate the various miRNAs indicated in the text (Table 1).
However, there are some limitations in the current studies. First, the physiological roles of miR-320 under normal conditions in various organs are missing. Second, the effect of miR-320 on glucose and lipid metabolism is not investigated by the mutual regulation of multiple organs. Furthermore, certain organs are composed of a variety of cell types, and different cell types may interact with each other by exosomes and other vesicles. Considering that the glucose and lipid metabolism disorder-associated diseases are systemic diseases, we should also pay attention to the interaction of miR-320 among certain organs and cell types. Third, studies have reported the roles of miR-320 in various disease conditions using animal models, for example, I/R injury, but the expression patterns of miR-320 in related patients were less investigated, which limited the clinical prospect. Finally, the mechanisms and functions of miR-320 were mainly investigated using expression vectors rather than genetically modified animal models. Although studies using miR-320 transgenic mice have been reported [150], up to now, the studies using miR-320 genetic knockout animal models have not been reported, which might be partially due to side effects on POLR3D. As reported previously, miR-320 is encoded directly upstream of the cell cycle gene POLR3D, which is a conserved subunit specific to RNA polymerase III and affects the overall function of the cell [19, 20]. It is worth noting that these models may be achieved by CRISPR-Cas9 or single base site-directed mutations, without affecting the function of POLR3D.

### Acknowledgements

We thank our colleagues in Dr. Wang’s group for technical assistance and stimulating discussions during the course of this investigation.

### Funding

This work was supported by grants from the National Natural Science Foundation of China (nos. 81822002, 31771264, and 31800973) and the Fundamental Research Funds for the Central Universities (2019kyXMBZ035). The funders had no role in study design, data collection and analysis, manuscript preparation, or decision to publish.

---

**Table 1. The expression changes of miRNAs in various metabolic associated-diseases.**

| miRNAs          | Diseases                        | Objectives               | Changes     | References                                 |
|-----------------|---------------------------------|--------------------------|-------------|--------------------------------------------|
| miR-320         | CHD                             | CHD patients             | Upregulated | J Cell Mol Med. 2015;19:970                |
|                 | Atherosclerosis                 | OPG−/− mouse             | Downregulated | PLoS One. 2017;12(3):e0174138              |
|                 | Diabetic cardiomyopathy         | db/db mice               | Upregulated | Circ Res. 2019;125:1106                    |
|                 | Diabetic nephropathy            | db/db mice               | Upregulated | Aging. 2019;11:3055                        |
|                 | Diabetes                        | T2DM patients            | Downregulated | Circ Res. 2010;107(6):810                  |
|                 | Diabetes                        | T2DM patients            | Upregulated | J Clin Endocrinol Metab. 2012;97:2221      |
|                 | Diabetes                        | insulin-resistant 3T3-L1 adipocytes | Upregulated | Clin Exp Phamacol Physiol. 2009;36:e32 |
|                 | Obesity                         | T2DM patients            | Upregulated | PLoS One. 2013;8:e72251                    |
|                 | Non-alcoholic fatty liver disease | CCl3 treated rats        | Upregulated | Toxicol Sci. 2018;166:228                   |
|                 | I/R injury                      | I/R mice                 | Upregulated | Cell Mol Biol Lett. 2018;23:41              |
|                 | I/R injury                      | myocardial I/R injury rats | Upregulated | Int J Mol Sci. 2015;16:1742               |
|                 | I/R injury                      | ischemic HPa2.cardiomyocytes | Upregulated | Cell Biochem Funct. 2018;36:166           |
|                 | Diabetes                        | type 2 diabetic GK rats  | Upregulated | Arterioscler Thromb Vasc Biol. 2004:24:435 |
|                 | Diabetic cardiomyopathy         | type 2 diabetic GK rats  | Upregulated | Clin Exp Pharmacol Physiol. 2009;36:181   |
|                 | Diabetic cardiomyopathy         | type 2 diabetic GK rats  | Upregulated | J Mol Cell Cardiol. 2014;74:139           |
|                 | Diabetes                        | high glucose treated with HUVECs | Upregulated | Biochem Biophys Res Commun. 2018;503:586 |
|                 | Hyperlipidemic                  | ox-LDL treated with HUVECs | Upregulated | J Nephrol. 2012;25:566                    |
|                 | Diabetic nephropathy            | STZ treated mice         | Upregulated | Surg Obes Relat Dis. 2018;14:960          |
|                 | Diabetes                        | DJB rats                 | Downregulated | Front Pharmacol. 2017;8:795                |
|                 | T2DM and hyperglycemia          | KK/Ay diabetic mice      | Upregulated | Mol Med Rep. 2016;14:1225                 |
|                 | Lung cancer                     | human lung adenocarcinoma tissues | Downregulated | Tumour Biol. 2014;35:4177                   |
|                 | Non-small cell lung cancer      | human NSCLC cell lines   | Downregulated | Cell Biochem Funct. 2018;36:166           |
|                 | Osteosarcoma                    | human osteosarcoma tissues | Downregulated | J Cell Mol Med. 2020;24(11):5984-5997      |
| miR-320e         | Hyperlipidemia                  | Hyperlipidemia patients  | Upregulated | J Cell Mol Med. 2020;24(11):5988-5997      |
| miRNA-425-3p, miRNA-933, miRNA-191, miR-320e, miR-320h | Hyperlipidemia                  | Hyperlipidemia patients  | Upregulated | J Cell Mol Med. 2020;24(11):5988-5997      |
| miR-206          | Hyperlipidemia                  | High-fat diet treated C57Bl/6J mice | Downregulated | J Hepatol. 2017;66:816                   |
|                 | CHD                             | CHD patients             | Upregulated | Biosci Rep. 2015;36:e00295                 |
| miR-574-5p       | CHD                             | CHD patients             | Upregulated | Biosci Rep. 2015;36:e00295                 |
| miR-92a          | Diabetes                        | Min-6 mouse pancreatic b-cell | Downregulated | Biochem Biophys Res Commun. 2018;500:577 |
| miR-142-3p       | CHD                             | CHD patients             | Upregulated | Medicine (Baltimore). 2018;97:e14128      |
| miR-17-5p        | CHD                             | CHD patients             | Upregulated | Medicine. 2018;97:e14128                  |
| miR-30e          | Atherosclerosis                 | coronary atherosclerosis patients | Upregulated | Mol Med Rep. 2019;19:3298                  |
| miR-138, miR-503, miR-367a | Atherosclerosis                 | T2DM patients            | Upregulated | PLoS One. 2013;8:e72251                    |

CHD, Coronary heart disease; T2DM, type 2 diabetes; I/R, ischemia-reperfusion injury; HUVECs, Human Umbilical Vein Endothelial Cells; ox-LDL, oxidative low-density lipoprotein; STZ, Streptozocin; DJB, Duodenal-jejunal bypass; NSCLC, non-small cell lung cancer.
Competing Interests

The authors have declared that no competing interest exists.

References

1. Aguilera M, Bruket T, Torres S, Liu B, Wong BJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015;313:1973-4.
2. Kurylowicz A, Cakala-Jakimowicz M, Puzianszewska-Kuznicka M. Targeting Ablominal Obesity and Its Compilations with Dietary Phytoestrogens. Nutrients. 2020; 12.
3. Yu A, Li J, Mengxue Y, Pan W, Changwei Y, Jie X. Identification of Nonylphenol and Chloplacid Metabolite-Related Proteins in the Serum of Type 2 Diabetes Patients. Iran J Public Health. 2019; 48: 2210-20.
4. Zhe ZY, Fang F, Ju CH, Xie ML. Apigenin-induced HIF-1alpha inhibitory factors in angina pectoris. J Mol Cell Cardiol. 2012; 50: 1492-9.
5. Wang F, Liu HC, Liu XS, Dong SN, Pan D, Yang LG, et al. Effects of omega-3 fatty acids on the regulation of protein oxidation and diabetes. Endocr Disord. 2017; 26: 17.
6. Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, et al. Association of chemerin mRNA expression in human adipose tissue with coronary atherosclerosis. Cardiovasc Diabetol. 2011; 10: 87.
7. Filla LA, Edwar L. Metabolomics in diabetic complications. Mol Biosyst. 2016; 12: 1090-105.
8. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011; 34 Suppl 1: S62-9.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97.
10. Qadir MI, Faheem A. miRNA: A Diagnostic and Therapeutic Tool for Type 2 Diabetes Mellitus. Diabetol Metab. 2016; 12: e0174138.
11. Kurylowicz A, Cakala-Jakimowicz M, Puzianowska-Kuznicka M. Targeting Ablominal Obesity and Its Compilations with Dietary Phytoestrogens. Nutrients. 2020; 12.
12. Zhao L, Cang Z, Sun H, Nie X, Wang N, Lu Y. Berberine improves glucosulfonylation diabetes in elderly rat. Leukot Essent Fatty Acids. 1988; 31: 181-97.
13. Gillett MJ. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7): 1327-1334. Clin Biochem Rev. 2009; 30: 197-200.
14. Newfield RS, Dewan AK, Jain S. Dyslipidemia in children with type 2 diabetes. J Intern Med. 2016; 17.
15. Forbes JM, Fotheringham AK. Vascular complications in diabetes: old messages, new thoughts. Diabetologia. 2017; 60: 2129-38.
16. Forbes JM, Fotheringham AK. Vascular complications in diabetes: old messages, new thoughts. Diabetologia. 2017; 60: 2129-38.
17. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007; 115: 3233-23.
18. Salisier AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001; 414: 799-806.
19. Holscher ME, Bode C, Bugger H. Diabetic Cardiomyopathy: Does the Type of Diabetes Matter? Int J Mol Sci. 2016; 17.
20. Kato M, Castro NE, Natarajan R. MicroRNAs: potential mediators and therapeutic targets for Type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2015; 3: e000473.
21. Kollberg JA, Jorgensen T, Gerwien RW, Hamren S, McKenna MP, Moler, E et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care. 2009; 32: 1207-12.
22. Aparicio-Puerta E, Jaspez D, Lebron R, Koppers-Lalic D, Marchal JA, et al. Atherosclerosis and Its Clinical Application. J Cardiovasc Transl Res. 2012: 10: 1051-60.
23. Yamagata A, Kikuchi A, Soma T, Takeda Y, Onishi M, et al. Secreted monocytic miR-150 expression profiles based on direct S-Poly(T)Plus assay for detection of coronary heart disease. PLoS One. 2017; 12: e0174138.
24. Li S, Zhai C, Wang X, Wang Y, Yang S, Li H, Zhao G, Wang F, et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One. 2011; 6: e28259.
25. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473: 317-25.
26. Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385: 117-71.
27. Wang Y, Yu Q, Fan D, Cao F. Coronary heart disease in type 2 diabetes: mechanisms and comprehensive prevention strategies. Expert Rev Cardiovasc Ther. 2012; 10: 1051-60.
28. Sharma A, Arbab-Zadeh A. Assessment of coronary heart disease by CT angiography: current and evolving applications. J Nucl Cardiol. 2012; 19: 796-806.
29. Generex R, Mehran R, Leon MB, Bettinger N, Stone GW. Classification for Assessing the Quality of Diagnostic Coronary Angiography. J Invasive Cardiol. 2017; 29: 417-20.
30. Zhou J, Shao G, Chen X, Yang X, Huang X, Peng P, et al. miRNA 206 and miRNA 574-5p are highly expressed in coronary artery disease. Biosci Rep. 2015; 36: e00295.
31. Zheng Z, Hou J, Zhang Q, Zhong W, Li L, Li C, et al. Circulating microRNA expression profiling and bioinformatics analysis of dysregulated microRNAs of patients with coronary artery disease. Medicine (Baltimore). 2018; 97: e11428.
32. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473: 317-25.
33. Gillett MJ. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7): 1327-1334. Clin Biochem Rev. 2009; 30: 197-200.
34. Kollberg JA, Jorgensen T, Gerwien RW, Hamren S, McKenna MP, Moler, E et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care. 2009; 32: 1207-12.
35. Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol. 2013; 9: 513-21.
36. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473: 317-25.
37. Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385: 117-71.
38. Wang Y, Yu Q, Fan D, Cao F. Coronary heart disease in type 2 diabetes: mechanisms and comprehensive prevention strategies. Expert Rev Cardiovasc Ther. 2012; 10: 1051-60.
39. Sharma A, Arbab-Zadeh A. Assessment of coronary heart disease by CT angiography: current and evolving applications. J Nucl Cardiol. 2012; 19: 796-806.
58. Sellers EA, Yung G, Dean HJ. Dyslipidemia and other cardiovascular risk factors in a Canadian First Nation population with type 2 diabetes mellitus. Pediatr Diabetes. 2007; 8: 384-90.

59. Basten M, Perez-Leinieux I, Despres JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis; 2014; 56: 369-81.

60. Viesi ACR, Salgado W, Jr, Pretti da Cunha Tirapelli d, dos Santos JS. The expression of PDGFR, IGF1 and II/II in obesity and the relationship with microRNAs. PLoS One. 2014; 9: e93512.

61. Heneghan HM, Miller N, McAnena OJ, O'Brien T, Kerin MJ. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J Clin Endocrinol Metab. 2011; 96: 1846-50.

62. Olumi AF. Commentary on ‘randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients.’ Wagner D, Trudel D, Van der Kwast T, Lonn GI, Greco A, Li D, et al. Cardiovasc Diabetol. 2013; 12: 60.

63. Pescador N, Perez-Barba M, Barra JM, Corbaton A, Martinez-Larrad MT, Heneghan HM, Miller N, McAnena OJ, O'Brien T, Kerin MJ. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J Clin Endocrinol Metab. 2011; 96: 1846-50.

64. Deng J, Liu S, Zou L, Xu C, Geng B, Xu G. Lipolysis response to endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Zhonghua Gan Zang Bing Za Zhi. 2018; 26: 865-8.

65. Heneghan HM, Miller N, McAnena OJ, O'Brien T, Kerin MJ. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J Clin Endocrinol Metab. 2011; 96: 1846-50.

66. van Dam EM, Govers R, James DE. Akt activation is required at a late stage of cell cycle progression in neuronal cytoskeletal defects. J Biol Chem. 2000; 275: 1407-12.

67. Qiao L, Li Y, Sun S. Insulin Exacerbates Inflammation in Fibroblast-Like Synoviocytes. Inflammation. 2020.

68. Leal-esteban LC, Fajas L. Cell cycle regulators in cancer cell metabolism. Biochim Biophys Acta Mol Basis Dis. 2020; 1866: 165715.

69. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006; 7: 85-96.

70. van Dam EM, Govers R, James DE. Akt activation is required at a late stage of cell cycle progression in neuronal cytoskeletal defects. J Biol Chem. 2000; 275: 1407-12.

71. Heim P, Morandi C, Brouwer GR, Xu L, Montessuit C, Brink M. Neuregulin-1 C-terminal cytoplasmic tails. J Biol Chem. 1999; 274: 13521-8.

72. Okada H, Woodcock-Mitchell J, Mitchell J, Sakamoto T, Marutuska K, Sobel BE, et al. Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression in rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen-centered free radicals. Circulation. 1998; 97: 2175-82.

73. Okruhlicova L, Tribulova N, Weismann P, Sotnikova R. Ultrastructure and histochemistry of rat myocardial capillary endothelial cells in response to diabetes and hypertension. Cell Res. 2005; 15: 532-8.

74. Yang N, Wu L, Zhao Y, Zou N, Liu C. MicroRNA-320 involves in the cardioprotective effect of insulin against myocardial ischemia by targeting survivin. J Mol Cell Cardiol. 2010; 430: 199-205.

75. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J. 2000; 349: 1-15.

76. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109: 121-30.

77. Farhangkhoee H, Khan ZA, Kaur H, Xin X, Chen S, Chakrabarti S. Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets. Circ Res. 2010; 106: 384-99.

78. Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res. 2001; 49: 554-60.

79. Delafragmante P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004; 24: 435-44.

80. Wang XH, Quan RZ, Zhang W, Chen SF, Jin HM, Hu RM. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-I in type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2009; 36: 181-8.
113. He Q, Xu RZ, Shikarian P, Pizzorno G, Lee-French CH, Rothman DL, et al. Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. Dis Markers. 2013; 19: 69-94.

114. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005; 65: 613-21.

115. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009; 23: 537-48.

116. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Guthrd B, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011; 17: 1498-503.

117. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2011; 41: 211-8.

118. Talvensaari KK, Lanning M, Tapanainen P, Knip M. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab. 1998; 81: 3051-5.

119. Nuuver J, Smit AJ, Postma S, Bleijtjer DT, Gietema JA. The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures. Cancer Treat Rev. 2002; 28: 195-214.

120. Poulain L, Sujebert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, et al. High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. Leukemia. 2017; 31: 2326-35.

121. Schaar DG, Medina DJ, Moore DJ, Straus RR, Ting Y. miR-320 targets transferin receptor 1 (CD71) and inhibits cell proliferation. Exp Hematol. 2009; 37: 245-55.

122. Scheperle T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Drysjot L, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008; 68: 6416-24.

123. Hsieh IS, Chang KC, Tsai YT, Ke JY, Li PH, Lee KH, et al. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis. 2013; 34: 530-8.

124. Luo L, Yang R, Zhao S, Chen Y, Hong S, Wang K, et al. Decreased miR-320 expression is associated with breast cancer progression, cell migration, and invasiveness via targeting Aquaporin 1. Acta Biochim Biophys Sin (Shanghai). 2018; 50: 473-80.

125. Pan C, Gao H, Zheng N, Gao Q, Si Y, Zhao Y. miR-320 inhibits the growth of glioma cells through downregulating FBX3. Biol Res. 2017; 50: 31.

126. Tang H, Lee M, Sharpe O, Salamone L, Noonan E, Hoang CD, et al. Oxidative stress-responsive microRNA-320 regulates glycolysis in diverse biological systems. FASEB J. 2012; 26: 4710-21.

127. Mukulukta BC, Yongky A, Daoutidou P, Hu WS. Bistability in glycolysis pathway as a physiological switch in energy metabolism. PLoS One. 2014; 9: e89756.

128. Lei T, Zhu Y, Jiang C, Wang Y, Fu J, Fan Z, et al. MicroRNA-320 was downregulated in non-small cell lung cancer and inhibited cell proliferation, migration and invasion by targeting fatty acid synthase. Mol Med Rep. 2016; 14: 1255-62.

129. Cheng C, Chen QZ, Shi XT. MicroRNA-320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthase. Tumour Biol. 2014; 35: 4177-83.

130. Menendez JA, Lupe R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007; 7: 763-77.

131. Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O’Connor K, et al. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 2012; 72: 1504-17.

132. Korzitszny EH, Street JM, Star EA, Yuen PS. Quantification of Exosomes. J Cell Physiol. 2017; 232: 1587-90.

133. Pan C, Stevic I, Muller V, Ni Q, Oliveira-Ferrer L, Pantel K, et al. Exosomal microRNAs as tumor markers in epithelial ovarian cancer. Mol Oncol. 2018; 12: 1935-48.

134. Beuzelin D, Pitard B, Kaefler B. Oral Delivery of miRNA With Lipidic Aminoglycoside Derivatives in the Breastfed Rat. Front Pharmacol. 2019; 10: 1037.

135. Gao X, Wan Z, Wei M, Dong Y, Zhao Y, Chen X, et al. Chronic myelogenous leukemia cells remodel the bone marrow niche via exosome-mediated transfer of miR-320. Theranostics. 2019; 9: 5642-56.

136. Manterola L, Guruceaga E, Gallego Perez-Larraya J, Gonzalez-Huarriz M, Jauregui P, Tejada S, et al. A small noncoding RNA signature found in c-maf/-/- mice kidney and c-maf overexpressed renal tubular cells. Biochem Biophys Res Commun. 2006; 348: 501-6.

137. Chen YQ, Wang XX, Yao XM, Zhang DL, Yang XF, Tian SF, et al. Altered microRNA-195 expression protected mesangial cells from apoptosis in early diabetic renal injury in mice. J Nephrol. 2012; 25: 566-76.

138. Bonnet F, Tikellis C, Kawachi H, Burns WC, Wooley PJ, Cao Z, et al. Nephrin expression in the post-natal developing kidney in normotensive and hypertensive rats. Clin Exp Hypertens. 2002; 24: 371-81.

139. Shihota S, Yoshida T, Sakai M, Kim JI, Sugihara H, Iishi T, et al. Correlation between the expression level of c-maf and glutathione peroxidase-3 in c-maf +/- mice kidney and c-maf overexpressed renal tubular cells. Biochem Biophys Res Commun. 2006; 348: 501-6.

140. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 2008; 74: 22-36.

141. Li M, Li H, Zhou Z, Zhou Y, Wang Y, Zhang X, et al. Duodenal-Jejunal Bypass Surgery Ameliorates Glucose Homeostasis and Reduces Endoplasmic Reticulum Stress in the Liver Tissue in a Diabetic Rat Model. Obes Surg. 2016; 26: 1002-9.

142. Wei G, Yi S, Yong D, Shaozhuang L, Guangyong Z, Sanyuan H. miR-320 mediates diabetes amelioration after duodenal-jejunal bypass via targeting adiponulin. Surg Obes Relat Dis. 2018; 14: 960-71.

143. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A. 2002; 99: 16309-13.

144. Yamazaki T, Kamen J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8: 1288-95.

145. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005; 1: 15-25.

146. Donath MY, Elsies JA, Maedler K, Schumann DM, Ellingsgaard H, Epper E, et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes. 2005; 54 Suppl 2: S108-13.

147. Mo FF, An T, Zhang ZJ, Liu YF, Liu HX, Pan YY, et al. Jiang Tang Xiao Ke Granule Play an Anti-diabetic Role in Diabetic Mice Pancreatic Tissue by Regulating the mRNAs and MicroRNAs Associated with PDK-Akt Signaling Pathway. Front Pharmacol. 2017; 8: 795.

148. Yu N, Fang X, Zhao D, Mu Q, Zuo J, Ma Y, et al. Anti-Diabetic Effects of Jiang Tang Xiao Ke Granule via PDK/Akt Signalling Pathway in Type 2 Diabetes KK/Ay Mice. PLoS One. 2017; 12: e0166980.

149. Suksangrat T, Phannasil P, Jitrapakdee S. miRNA Regulation of Glucose and Lipid Metabolism in Relation to Diabetes and Non-alcoholic Fatty Liver Disease. Adv Exp Med Biol. 2019; 1134: 129-48.

150. Ren XP, Wu J, Wang X, Sarot MA, Jones K, Qian J, et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation. 2009; 119: 2357-66.